Biosimilar drugs step up complexity


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

Johnson & Johnson still has patent protection for Remicade in the majority of European countries. This means that the biosimilars, if finally approved, will either have to launch first in peripheral markets, or try to overturn the patent in court.


Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Indian U-turn on diabetes drug ban

16 August 2013 News and Analysis

news image

Suspension of cheap and popular medicine reversed but will now come with new safety warnings

DNA waves don't wash

10 July 2013 The Crucible

news image

Philip Ball asks why a spectacular claim seems to have been overlooked. Sometimes science doesn’t work the way it’s suppo...